References
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock. Crit Care Med. 2017;45(3):486–552.
- Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211. doi:https://doi.org/10.1016/S0140-6736(19)32989-7.
- van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407–420. doi:https://doi.org/10.1038/nri.2017.36.
- Busch LM, Sun J, Cui X, Eichacker PQ, Torabi-Parizi P. Checkpoint inhibitor therapy in preclinical sepsis models: a systematic review and meta-analysis. Intensive Care Med Exp. 2020;8(1):7.
- Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol. 1989;7:445–480. doi:https://doi.org/10.1146/annurev.iy.07.040189.002305.
- Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180–205. doi:https://doi.org/10.1111/j.1600-065X.2011.01011.x.
- Edner NM, Carlesso G, Rush JS, Walker LSK. Targeting co-stimulatory molecules in autoimmune disease. Nat Rev Drug Discov. 2020;19(12):860–883. doi:https://doi.org/10.1038/s41573-020-0081-9.
- Wang R, Fang Q, Zhang L, et al. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol. 1997;158(6):2856–2861.
- Svedova J, Tsurutani N, Liu W, Khanna KM, Vella AT. TNF and CD28 signaling play unique but complementary roles in the systemic recruitment of innate immune cells after Staphylococcus aureus enterotoxin A inhalation. J Immunol. 2016;196(11):4510–4521. doi:https://doi.org/10.4049/jimmunol.1600113.
- Kaempfer R, Popugailo A, Levy R, Arad G, Hillman D, Rotfogel Z. Bacterial superantigen toxins induce a lethal cytokine storm by enhancing B7-2/CD28 costimulatory receptor engagement, a critical immune checkpoint. Receptors Clin Investig. 2017;4(1):e1500.
- Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028. doi:https://doi.org/10.1056/NEJMoa063842.
- Eastwood D, Findlay L, Poole S, et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol. 2010;161(3):512–526. doi:https://doi.org/10.1111/j.1476-5381.2010.00922.x.
- Langenhorst D, Tabares P, Gulde T, et al. Self-recognition sensitizes mouse and human regulatory T cells to low-dose CD28 superagonist stimulation. Front Immunol. 2017;8:1985. doi:https://doi.org/10.3389/fimmu.2017.01985.
- Bulger EM, Maier RV, Sperry J, et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 2014;149(6):528–536. doi:https://doi.org/10.1001/jamasurg.2013.4841.
- Ramachandran G, Kaempfer R, Chung CS, et al. CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis. J Infect Dis. 2015;211(6):995–1003. doi:https://doi.org/10.1093/infdis/jiu556.
- Kurup SP, Obeng-Adjei N, Anthony SM, et al. Regulatory T cells impede acute and long-term immunity to blood-stage malaria through CTLA-4. Nat Med. 2017;23(10):1220–1225. doi:https://doi.org/10.1038/nm.4395.
- Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock. 2011;36(1):38–44. doi:https://doi.org/10.1097/SHK.0b013e3182168cce.
- Gimmi CD, Freeman GJ, Gribben JG, Sugita K, et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA. 1991;88(15):6575–6579. doi:https://doi.org/10.1073/pnas.88.15.6575.
- Nolan A, Kobayashi H, Naveed B, et al. Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis. PLoS One. 2009;4(8):e6600. doi:https://doi.org/10.1371/journal.pone.0006600.
- Newton S, Ding Y, Chung CS, Chen Y, Lomas-Neira JL, Ayala A. Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response. Surg Infect (Larchmt). 2004;5(4):375–383. doi:https://doi.org/10.1089/sur.2004.5.375.
- Wang C, Gui Q, Zhang K. Functional polymorphisms in CD86 gene are associated with susceptibility to pneumonia-induced sepsis. APMIS. 2015;123(5):433–438. doi:https://doi.org/10.1111/apm.12364.
- Song H, Tang L, Xu M, et al. CD86 polymorphism affects pneumonia-induced sepsis by decreasing gene expression in monocytes. Inflammation. 2015;38(2):879–885. doi:https://doi.org/10.1007/s10753-014-9997-8.
- Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci. 2015;36(9):587–595. doi:https://doi.org/10.1016/j.tips.2015.06.005.
- Goyert SM, Silver J. Editorial: PD-1, a new target for sepsis treatment: better late than never. J Leukoc Biol. 2010;88(2):225–226. doi:https://doi.org/10.1189/jlb.0410240.
- Zhang Y, Zhou Y, Lou J, et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care. 2010;14(6):R220. doi:https://doi.org/10.1186/cc9354.
- Tomino A, Tsuda M, Aoki R, et al. Increased PD-1 expression and altered T cell repertoire diversity predict mortality in patients with septic shock: a preliminary study. PLoS One. 2017;12(1):e0169653. doi:https://doi.org/10.1371/journal.pone.0169653.
- Huang X, Chen Y, Chung CS, et al. Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. J Immunol. 2014;192(3):1091–1099. doi:https://doi.org/10.4049/jimmunol.1302252.
- Shao R, Fang Y, Yu H, Zhao L, Jiang Z, Li CS. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit Care. 2016;20(1):124. doi:https://doi.org/10.1186/s13054-016-1301-x.
- Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS. Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233–240. doi:https://doi.org/10.1189/jlb.0110037.
- Ayala A, Elphick GF, Kim YS, et al. Sepsis-induced potentiation of peritoneal macrophage migration is mitigated by programmed cell death receptor-1 gene deficiency. J Innate Immun. 2014;6(3):325–338. doi:https://doi.org/10.1159/000355888.
- Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS. Frontline Science: defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol. 2016;100(6):1239–1254. doi:https://doi.org/10.1189/jlb.4HI0616-255R.
- Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014;18(1):R3. doi:https://doi.org/10.1186/cc13176.
- Phares TW, Kotraiah V, Chung CS, et al. A peptide-based checkpoint immunomodulator alleviates immune dysfunction in murine polymicrobial sepsis. Shock. 2020. doi:https://doi.org/10.1097/SHK.0000000000001682. [Epub ahead of print].
- Grimaldi D, Pradier O, Hotchkiss RS, Vincent JL. Nivolumab plus interferon-γ in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18. doi:https://doi.org/10.1016/S1473-3099(16)30541-2.
- Watanabe E, Nishida O, Kakihana Y, et al. Pharmacokinetics, pharmacodynamics and safety of nivolumab in patients with sepsis-induced immunosuppression: a multicenter, open-label phase 1/2 study. Shock. 2020;53(6):686–694. doi:https://doi.org/10.1097/SHK.0000000000001443.
- Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab. Intensive Care Med. 2019;45(10):1360–1371. doi:https://doi.org/10.1007/s00134-019-05704-z.
- Hotchkiss RS, Colston E, Yende S, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47(5):632–642. doi:https://doi.org/10.1097/CCM.0000000000003685.
- Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–172. doi:https://doi.org/10.1111/j.1600-065X.2009.00782.x.
- Rickert RC, Jellusova J, Miletic AV. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244(1):115–133. doi:https://doi.org/10.1111/j.1600-065X.2011.01067.x.
- Ford ML. T cell cosignaling molecules in transplantation. Immunity. 2016;44(5):1020–1033. doi:https://doi.org/10.1016/j.immuni.2016.04.012.
- Sugimoto K, Galle C, Preiser JC, Creteur J, Vincent JL, Pradier O. Monocyte CD40 expression in severe sepsis. Shock. 2003;19(1):24–27.
- Nolan A, Weiden M, Kelly A, et al. CD40 and CD80/86 act synergistically to regulate inflammation and mortality in polymicrobial sepsis. Am J Respir Crit Care Med. 2008;177(3):301–308. doi:https://doi.org/10.1164/rccm.200703-515OC.
- Sinistro A, Almerighi C, Ciaprini C, et al. Downregulation of CD40 ligand response in monocytes from sepsis patients. Clin Vaccine Immunol. 2008;15(12):1851–1858. doi:https://doi.org/10.1128/CVI.00184-08.
- Sinistro A, Ciaprini C, Natoli S, et al. Lipopolysaccharide desensitizes monocytes-macrophages to CD40 ligand stimulation. Immunology. 2007;122(3):362–370. doi:https://doi.org/10.1111/j.1365-2567.2007.02648.x.
- Schwulst SJ, Grayson MH, DiPasco PJ, et al. Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol. 2006;177(1):557–565. doi:https://doi.org/10.4049/jimmunol.177.1.557.
- Scott MJ, Hoth JJ, Stagner MK, Gardner SA, Peyton JC, Cheadle WG. CD40-CD154 interactions between macrophages and natural killer cells during sepsis are critical for macrophage activation and are not interferon gamma dependent. Clin Exp Immunol. 2004;137(3):469–477. doi:https://doi.org/10.1111/j.1365-2249.2004.02547.x.
- Michels M, Danieslki LG, Vieira A, et al. CD40-CD40 ligand pathway is a major component of acute neuroinflammation and contributes to long-term cognitive dysfunction after sepsis. Mol Med. 2015;21:219–226. doi:https://doi.org/10.2119/molmed.2015.00070.
- Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood. 2006;108(7):2455–2462. doi:https://doi.org/10.1182/blood-2006-04-017251.
- Lorente L, Martin MM, Perez-Cejas A, et al. Non-survivor septic patients have persistently higher serum sCD40L levels than survivors. J Crit Care. 2017;41:177–182. doi:https://doi.org/10.1016/j.jcrc.2017.05.021.
- Lorente L, Martin MM, Varo N, et al. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care. 2011;15(2):R97. doi:https://doi.org/10.1186/cc10104.
- Rahman M, Zhang S, Chew M, Syk I, Jeppsson B, Thorlacius H. Platelet shedding of CD40L is regulated by matrix metalloproteinase-9 in abdominal sepsis. J Thromb Haemost. 2013;11(7):1385–1398. doi:https://doi.org/10.1111/jth.12273.
- Rahman M, Zhang S, Chew M, Ersson A, Jeppsson B, Thorlacius H. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg. 2009;250(5):783–790. doi:https://doi.org/10.1097/SLA.0b013e3181bd95b7.
- Chew M, Rahman M, Ihrman L, Erson A, Zhang S, Thorlacius H. Soluble CD40L (CD154) is increased in patients with shock. Inflamm Res. 2010;59(11):979–982. doi:https://doi.org/10.1007/s00011-010-0213-5.
- Varo N, de Lemos JA, Libby P, et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation. 2003;108(9):1049–1052. doi:https://doi.org/10.1161/01.CIR.0000088521.04017.13.
- Ward-Kavanagh LK, Lin WW, Sedy JR, Ware CF. The TNF receptor superfamily in co-stimulating and co-inhibitory responses. Immunity. 2016;44(5):1005–1019. doi:https://doi.org/10.1016/j.immuni.2016.04.019.
- Karulf M, Kelly A, Weinberg AD, Gold JA. OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol. 2010;185(8):4856–4862. doi:https://doi.org/10.4049/jimmunol.1000404.
- Nguyen QT, Ju SA, Park SM, et al. Blockade of CD137 signaling counteracts polymicrobial sepsis induced by cecal ligation and puncture. Infect Immun. 2009;77(9):3932–3938. doi:https://doi.org/10.1128/IAI.00407-09.
- Vinay DS, Choi BK, Bae JS, Kim WY, Gebhardt BM, Kwon BS. CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol. 2004;173(6):4218–4229. doi:https://doi.org/10.4049/jimmunol.173.6.4218.
- Bang BR, Kim SJ, Yagita H, Croft M, Kang YJ. Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice. Eur J Immunol. 2015;45(3):886–892. doi:https://doi.org/10.1002/eji.201445174.
- Ma J, Bang BR, Lu J, et al. The TNF family member 4-1BBL sustains inflammation by interacting with TLR signaling components during late-phase activation. Sci Signal. 2013;6(295):ra87. doi:https://doi.org/10.1126/scisignal.2004431.
- Nguyen QT, Nguyen TH, Ju SA, et al. CD137 expressed on neutrophils plays dual roles in antibacterial responses against Gram-positive and Gram-negative bacterial infections. Infect Immun. 2013;81(6):2168–2177. doi:https://doi.org/10.1128/IAI.00115-13.
- Murphy TL, Murphy KM. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu Rev Immunol. 2010;28:389–411. doi:https://doi.org/10.1146/annurev-immunol-030409-101202.
- Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6(1):90–98. doi:https://doi.org/10.1038/ni1144.
- Shui JW, Steinberg MW, Kronenberg M. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J Leukoc Biol. 2011;89(4):517–523. doi:https://doi.org/10.1189/jlb.0910528.
- Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A. B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care. 2013;17(6):R276. doi:https://doi.org/10.1186/cc13131.
- Lange A, Sunden-Cullberg J, Magnuson A, Hultgren O. Soluble B and T lymphocyte attenuator correlates to disease severity in sepsis and high levels are associated with an increased risk of mortality. PLoS One. 2017; 12(1):e0169176. doi:https://doi.org/10.1371/journal.pone.0169176.
- Shao R, Li CS, Fang Y, Zhao L, Hang C. Low B and T lymphocyte attenuator expression on CD4+ T cells in the early stage of sepsis is associated with the severity and mortality of septic patients: a prospective cohort study. Crit Care. 2015;19(1):308. doi:https://doi.org/10.1186/s13054-015-1024-4.
- Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010;235(1):172–189. doi:https://doi.org/10.1111/j.0105-2896.2010.00903.x.
- Rodriguez-Manzanet R, DeKruyff R, Kuchroo VK, Umetsu DT. The costimulatory role of TIM molecules. Immunol Rev. 2009;229(1):259–270. doi:https://doi.org/10.1111/j.1600-065X.2009.00772.x.
- Wang F, Hou H, Xu L, et al. Tim-3 signaling pathway as a novel negative mediator in lipopolysaccharide-induced endotoxic shock. Hum Immunol. 2014;75(5):470–478. doi:https://doi.org/10.1016/j.humimm.2014.02.001.
- Yang X, Jiang X, Chen G, et al. T cell Ig mucin-3 promotes homeostasis of sepsis by negatively regulating the TLR response. J Immunol. 2013;190(5):2068–2079. doi:https://doi.org/10.4049/jimmunol.1202661.
- Yao Y, Deng H, Li P, et al. α-lactose improves the survival of septic mice by blockade of TIM-3 signaling to prevent NKT cell apoptosis and attenuate cytokine storm. Shock. 2017;47(3):337–345. doi:https://doi.org/10.1097/SHK.0000000000000717.
- Ren F, Li J, Jiang X, et al. Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes. Tissue Antigens. 2015;86(5):325–332. doi:https://doi.org/10.1111/tan.12653.
- Rudick CP, Cornell DL, Agrawal DK. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis. Expert Rev Clin Immunol. 2017;13(9):907–919. doi:https://doi.org/10.1080/1744666X.2017.1357469.
- Chang KC, Burnham CA, Compton SM, et al. Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care. 2013;17(3):R85. doi:https://doi.org/10.1186/cc12711.